ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic sclerosis"

  • Abstract Number: 2471 • ACR Convergence 2024

    Association of Telangiectasias with Autoantibodies and Clinical Manifestations in Systemic Sclerosis

    Namitha Nair1, Thomas Medsger, Jr2, Robert Lafyatis3, Maureen Laffoon4, Leigh Freno4 and Robyn Domsic5, 1University of Pittsburgh Medical Center, Pittsburgh, PA, 2Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, 3University of Pittsburgh, Pittsburgh, PA, 4UPMC, Pittsburgh, PA, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA

    Background/Purpose: Telangiectasias (Tel) are visibly dilated cutaneous post-capillary venules reported to occur in about 75% of patients with systemic sclerosis (SSc), making them a common…
  • Abstract Number: 0350 • ACR Convergence 2024

    Piloting an Adaptation of the Making It Work Program for Systemic Sclerosis: Promising Effects on Job Related Self-efficacy and Risk of Work Disability

    Janet Poole1, Kristine Carandang2, Mary Thelander Hill1, Jessica Salazar1, Anna Koch3, Timothy Dionne1 and Diane Lacaille4, 1University of New Mexico, Albuquerque, NM, 2Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, 3Comfy Couch Counseling LLC, Albuquerque, NM, 4Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Although work disability presents a substantial burden for people with systemic sclerosis (SS), there are no tailored programs that aim to support their employment.…
  • Abstract Number: 0709 • ACR Convergence 2024

    Linear Combination of Principal Components Achieves Top Performance in Identifying Rheumatologist-Diagnosed Systemic Sclerosis from Electronic Health Records

    Yiming Luo, Gongbo Zhang, Chunhua Weng and Elana Bernstein, Columbia University Irving Medical Center, New York, NY

    Background/Purpose: Systemic sclerosis (SSc) is a rare systemic autoimmune rheumatic disease. International Classification of Diseases (ICD) code counts (for example, using ≥ 2 ICD-10 codes…
  • Abstract Number: 0960 • ACR Convergence 2024

    The Esophageal Epithelium in Systemic Sclerosis: Cellular and Molecular Dysregulation Revealed by Single-Cell RNA Sequencing

    Matthew Dapas1, Margarette Clevenger1, Hadijat Makinde2, Tyler Therron1, Dustin Carlson1, Mary Carns3, Kathleen Aren3, Carrie Richardson2, Cenfu Wei2, Lutfiyya Muhammad4, John Pandolfino1, Harris Perlman2, Deborah Winter5 and Marie-Pier Tetreault1, 1Northwestern University, Chicago, 2Northwestern University, Chicago, IL, 3Northwestern University Division of Rheumatology, Chicago, IL, 4Northwestern Feinberg School of Medicine, Chicago, IL, 5Northwestern University, Skokie, IL

    Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by vasculopathy and progressive fibrosis of the skin and internal organs. Individuals with SSc often…
  • Abstract Number: 1567 • ACR Convergence 2024

    Systemic Sclerosis Is Associated with Sub-Clinical Abnormalities in Myocardial Energetics, Perfusion and Increased Fibrosis

    Chin Yit Soo1, Nicholas Jex2, Stefano Di Donato3, Lucy Elizabeth Thornton4, Vishal Kakkar5, Riccardo Bixio6, Raluca Tomoaia1, Thomas Anderton2, May Lwin2, Christel Kamani2, Amrit Chowdhary2, Henry Procter1, Sharmaine Thirunavukarasu1, Sindhoora Kotha2, Marilena Giannoudi2, Eylem Levelt2, Sven Plein1, Francesco Delgado6 and Lesley-Anne Bissell7, 1Multidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, University of Leeds, Leeds, United Kingdom., Leeds, England, United Kingdom, 2Multidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, University of Leeds, Leeds, United Kingdom., Leeds, United Kingdom, 31. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, 41. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, 5University of Leeds, Leeds, United Kingdom, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom., Leeds, United Kingdom, 7Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Primary cardiac involvement in systemic sclerosis (SSc) is heterogenous, poorly defined and associated with significant cardiac morbidity and mortality. The underlying mechanism is not…
  • Abstract Number: 1590 • ACR Convergence 2024

    Milder ILD with Preserved Lung Function Significantly Contributes to Respiratory Caused Mortality in SSc

    Anna-Maria Hoffmann-Vold1, Håvard Fretheim1, Emily Langballe2, Hilde Jenssen Bjørkekjær3, Henriette Didriksen1, Phuong Phuong Diep4, Anna Helena Andersson1, Ragnar Gunnarsson1, Michael T Durheim1, Torhild Garen1, Øyvind Midtvedt5, Trond Mogens Aaløkken6, Øyvind Molberg7 and Oliver Distler8, 1Oslo University Hospital, Oslo, Norway, 2Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 3Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Kristiansand, Norway, 4Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, 5Oslo University Hospital, Oslo, Oslo, Norway, 6Medicine, Oslo, Norway, Oslo, Norway, 7Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 8Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). While impaired lung function with forced vital capacity (FVC) <…
  • Abstract Number: 1827 • ACR Convergence 2024

    Characterization of Fibroblast Subpopulations and Their Cellular Local Environments in Systemic Sclerosis Using Imaging Mass Cytometry

    Aleix Rigau1, Minrui Liang2, Veda Devakumar2, Ranjana Neelagar2, Alexandru-Emil Matei2, Andrea-Hermina Györfi2, Christina Bergmann3, Tim Filla2, Vladyslav Fedorchenko1, Georg Schett4, Jörg Distler5 and Yi-Nan Li2, 1Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 2Universitätsklinikum Düsseldorf and Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany, 3Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, 4Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 5Universitätsklinikum Düsseldorf and Heinrich-Heine-Universität Düsseldorf, Duesseldorf, Germany

    Background/Purpose: Single-cell transcriptomic data has shown that fibroblasts exhibit heterogeneity, with subpopulations that have diverse functional characteristics. However, the conventional single-cell methods are unable to…
  • Abstract Number: 2445 • ACR Convergence 2024

    Effects of Aminaphtone on TGF-beta1 Serum Concentration as Concomitant Treatment to Standard Therapy in Systemic Sclerosis Patients: A Pilot Study

    Alberto Sulli1, Stefano Soldano2, Rosanna Campitiello3, Elvis Hysa4, Tamara Vojinovic5, Carmen Pizzorni6, Sabrina Paolino7, Maurizio Cutolo5 and Emanuele Gotelli5, 1Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Genova, Italy, 2Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Liguria, Italy, 3Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Liguria, Italy, 4Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, 5Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, 6Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, 7Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Specialties (Di.M.I.), University of Genova; IRCCS Ospedale Policlinico San Martino, Genova, Liguria, Italy

    Background/Purpose: Aminaphtone (AMI) is a vasoactive drug licensed to treat microvascular disorders and able to increase peripheral blood perfusion and to reduce Raynaud's phenomenon (RP)…
  • Abstract Number: 2475 • ACR Convergence 2024

    The Critical Role of Annual HRCT in Identifying ILD Progression and Assessing Outcome in SSc

    Anna-Maria Hoffmann-Vold1, Simon Beyeler2, Liubov Petelytska3, Håvard Fretheim1, Trond Mogens Aaløkken4, Mike Becker5, Hilde Jenssen Bjørkekjær6, Cathrine Brunborgg1, Cosimo Bruni7, Christian Clarenbach8, Phuong Phuong Diep9, Rucsandra Dobrota7, Michael T Durheim1, Muriel Elhai10, Thomas Frauenfelder8, Suzana Jordan7, Emily Langballe11, Øyvind Midtvedt12, Carina Mihai7, Adela Sarbu8, Marco Sprecher8, Øyvind Molberg13 and Oliver Distler14, 1Oslo University Hospital, Oslo, Norway, 2University Hospital Zurich, Zürich, Zurich, Switzerland, 3University Hospital Zurich, Zurich, Switzerland, 4Medicine, Oslo, Norway, Oslo, Norway, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 6Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Kristiansand, Norway, 7University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8University Hospital Zurich, Zurich, Zurich, Switzerland, 9Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, 10University Hospital zurich, Zürich, Switzerland, 11Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 12Oslo University Hospital, Oslo, Oslo, Norway, 13Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 14Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc). Monitoring with lung function testing every 3–6 months for…
  • Abstract Number: 0677 • ACR Convergence 2024

    Patterns of Raynaud’s Phenomenon Management in Patients with Systemic Sclerosis: A Real-World Data from Community-Based Practices in the United States

    Gulsen Ozen1, Sofia Pedro2, Kaleb Michaud3 and Robyn Domsic4, 1University of Nebraska Medical Center, Bellevue, NE, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3University of Nebraska Medical Center, Omaha, NE, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA

    Background/Purpose: Raynaud’s phenomenon (RP) and the complex vasculopathy of systemic sclerosis (SSc) can lead to chronic digital ischemia, ulcerations, and necrosis with significant pain and…
  • Abstract Number: 0711 • ACR Convergence 2024

    Molecular Signatures in the Skin as Predictors of Longitudinal Clinical Trajectories in Patients with Systemic Sclerosis

    Natania Field1, Monica Yang2, Niket Gupta1, Maxwell Shramuk1, Lutfiyya Muhammad1, Vivien Goh1, Monica Espinoza3, Yiwei Yuan3, Rezvan Parvizi3, Kathleen Aren4, Mary Carns4, Isaac Goldberg5, Lorinda Chung6, Dinesh Khanna7, Zsuzsanna McMahan8, Michael Whitfield3 and Monique Hinchcliff9, 1Northwestern Feinberg School of Medicine, Chicago, IL, 2UCSF, San Francisco, CA, 3Geisel School of Medicine at Dartmouth, Hanover, NH, 4Northwestern University Division of Rheumatology, Chicago, IL, 5Wayne State University School of Medicine, Detroit, MI, 6Stanford University, Woodside, CA, 7University of Michigan, Ann Arbor, MI, 8UTHealth Houston Division of Rheumatology, Houston, TX, 9Yale School of Medicine, Westport, CT

    Background/Purpose: It has become clear that classification by phenotype is insufficient to explain the heterogeneity in clinical progression for many rheumatic diseases. Systemic sclerosis (SSc)…
  • Abstract Number: 0962 • ACR Convergence 2024

    Characterizing the Contribution of Myeloid Cells to Limited and Diffuse Cutaneous Systemic Sclerosis

    Parker Jones1, Salina Dominguez2, Miranda Gurra3, Gaurav Gadhvi4, Tyler Therron2, Kathleen Aren5, Carla Cuda3, Monique Hinchcliff6, Harris Perlman3, Hadijat Makinde3 and Deborah Winter7, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Northwestern University, Chicago, 3Northwestern University, Chicago, IL, 4University of Michigan, Ann Arbor, MI, 5Northwestern University Division of Rheumatology, Chicago, IL, 6Yale School of Medicine, Westport, CT, 7Northwestern University, Skokie, IL

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by multiorgan fibrosis. The two main subtypes are diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc…
  • Abstract Number: 1569 • ACR Convergence 2024

    Scleroderma Renal Crisis – Different Phenotypes and Patient Trajectories

    Katya Dolnikov1, Kochava Toledano1, Marius Braun2, Doron Markovits1, Sami Giryes1, Yonit Tavor1, Alexandra Balbir-Gurman3 and Yolanda Braun Moscovici1, 1Rheumatology Institute, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion-Israeli Institute of Technology, HAIFA, Israel, 2Liver Insitute, Beilinson Hospital, Petach Tikva, Petach Tikva, Israel, 3Rheumatology Institute, Rambam Health Care Campus and The Rappaport Faculty of |Medicine, Technion, Haifa, Israel

    Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening complication that occurs in a minority of patients, particularly those with diffuse cutaneous systemic sclerosis ( SSc).…
  • Abstract Number: 1643 • ACR Convergence 2024

    Single Nuclei Multiome and Spatial Transcriptomic Analysis of Early, Untreated SSc Skin Identifies Signaling Interactions Between Macrophages and Fibroblasts

    Helen Jarnagin1, Dillon Popovich2, Rezvan Parvizi3, Rosemary Gedert4, Lam C. Tsoi5, Rachael Wasikowski5, Zhiyun Gong1, Madeline Morrisson6, Laurent Perreard7, Fred Kolling IV7, Dinesh Khanna4, Johann Gudjonsson4 and Michael Whitfield3, 1Dartmouth College, Lebanon, NH, 2Dartmouth College, West Lebanon, NH, 3Geisel School of Medicine at Dartmouth, Hanover, NH, 4University of Michigan, Ann Arbor, MI, 5Michigan, Dept. of Dermatology, Ann Arbor, MI, 6Geisel School of Medicine at Dartmouth College, Hanover, NH, 7Geisel School of Medicine, Dartmouth College, Lebanon

    Background/Purpose: We generated a vertically integrated dataset on treatment naïve patients with dcSSc (diffuse Systemic Sclerosis) skin that includes bulk RNA-seq, single nuclei multiome, and…
  • Abstract Number: 1828 • ACR Convergence 2024

    SSc Fibroblasts Trigger a Systemic Type I Interferon Response in SSc Patients Through Canonical TGF-β Receptor Signalling

    Christopher Wasson1, Stefano Di Donato2, Rebecca Ross3, Vishal Kakkar4 and Francesco Del Galdo1, 1University of Leeds, Leeds, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 3Medicine and Health, University of Leeds, Leeds, United Kingdom, 4LIRMM University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic Sclerosis is an autoimmune disease which is characterized by fibrosis of the skin and the internal organs with variable severity. Type I interferon…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 46
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology